National Oncology Institute

The medical center is at the forefront of oncology research, focusing on advanced solid tumors. The institution is pioneering studies on the safety and tolerability of novel therapeutic agents, such as PF-07220060, in various cancer types including breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, colorectal cancer (CRC), and liposarcoma. These efforts aim to identify optimal dosing regimens and enhance treatment efficacy.

• Breast Cancer
• Prostate Cancer
• Colorectal Cancer
• Liposarcoma

By exploring the effects of combination therapies and the impact of genetic amplifications, the center is contributing significantly to personalized cancer treatment strategies.

Specializing in melanoma, the center is conducting advanced studies on treatment-resistant forms of the disease. Research includes evaluating the efficacy of combination therapies involving encorafenib, binimetinib, and pembrolizumab for patients with BRAF V600E/K mutation-positive melanoma. These studies aim to improve response rates and progression-free survival in patients who have progressed after prior treatments.

• BRAF V600E/K Mutation-Positive Melanoma
• Unresectable or Metastatic Melanoma

The center's work is pivotal in developing new therapeutic options for melanoma, particularly for those with limited treatment success.

The institution is a leader in the study of hematologic malignancies, with a focus on chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Current research includes evaluating the combination of lisaftoclax and acalabrutinib to improve progression-free survival in previously treated patients. Additionally, the center is exploring novel treatment regimens for follicular lymphoma using epcoritamab in combination with rituximab and lenalidomide.

• Chronic Lymphocytic Leukemia (CLL)
• Small Lymphocytic Lymphoma (SLL)
• Follicular Lymphoma

These studies are crucial for advancing treatment protocols and improving outcomes for patients with these challenging blood cancers.

Focusing on breast cancer, the center is investigating new treatment avenues for triple-negative breast cancer (TNBC). Research includes comparing the efficacy of sacituzumab govitecan against standard treatments in patients with locally advanced or metastatic TNBC. This work is essential for developing more effective therapies for this aggressive cancer subtype.

• Triple-Negative Breast Cancer (TNBC)
• PD-L1-negative Metastatic Breast Cancer

By addressing the unique challenges of TNBC, the center is contributing to the development of targeted therapies that offer hope for improved patient outcomes.